Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
Investor presentation - Botanix Pharmaceuticals Ltd
Health
Botanix Pharma aims to develop next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
announcement | t+2 movement | date |
---|---|---|
| - | 22 Jan 2021 |
| +22.22% | 19 Jan 2021 |
| +4.17% | 17 Dec 2020 |
| -7.69% | 13 Dec 2020 |
| -7.69% | 23 Nov 2020 |
| -7.69% | 23 Nov 2020 |
| +10.53% | 10 Nov 2020 |
| +6.38% | 21 Oct 2020 |
| +6.38% | 21 Oct 2020 |
| +10.00% | 12 Oct 2020 |
Current Price
52WK HIGH
52WK LOW
1YR RETURN
1YR RETURN VS. SECTOR
90 DAY RETURN
ASX RANK
/2,048
SECTOR RANK
/168
SHARES OUTSTANDING
Health
Botanix Pharma aims to develop next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
ASX:BOT is not raising right now
Want to invest?
(03) 9028 2888
clients@freshequities.com
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia